Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) EBITDA (2022 - 2025)

Bioregenx has reported EBITDA over the past 4 years, most recently at -$1.0 million for Q4 2025.

  • For Q4 2025, EBITDA rose 94.47% year-over-year to -$1.0 million; the TTM value through Dec 2025 reached -$1.5 million, up 93.29%, while the annual FY2025 figure was -$1.5 million, 93.29% up from the prior year.
  • EBITDA for Q4 2025 was -$1.0 million at Bioregenx, down from -$73343.0 in the prior quarter.
  • Over five years, EBITDA peaked at $18209.0 in Q3 2022 and troughed at -$18.4 million in Q4 2024.
  • A 4-year average of -$1.8 million and a median of -$263301.5 in 2023 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: tumbled 13934.01% in 2023 and later surged 94.47% in 2025.
  • Year by year, EBITDA stood at -$5535.0 in 2022, then crashed by 4555.65% to -$257690.0 in 2023, then crashed by 7039.04% to -$18.4 million in 2024, then surged by 94.47% to -$1.0 million in 2025.
  • Business Quant data shows EBITDA for BRGX at -$1.0 million in Q4 2025, -$73343.0 in Q3 2025, and -$185542.0 in Q2 2025.